Remove Gene Remove Gene Editing Remove Regulation
article thumbnail

Vertex, CRISPR strengthen case for pioneering gene-editing treatment

Bio Pharma Dive

Positive data from 75 patients with either sickle cell disease or beta thalassemia keep the companies’ therapy on track to become the first CRISPR-based treatment submitted to drug regulators, possibly by the end of the year.

article thumbnail

FDA sets decision dates for Vertex, CRISPR gene editing drug

Bio Pharma Dive

The regulator will issue separate verdicts on the pioneering treatment’s use in sickle cell disease and beta thalassemia, with the first expected late this year.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

In first, Verve gets clearance to test base editing inside the body

Bio Pharma Dive

Regulators in New Zealand have allowed human testing to proceed, another milestone for the gene editing technology. Verve plans to soon ask for approval to begin testing in the U.S.

article thumbnail

Bluebird, playing catch-up, gets decision date for sickle cell gene therapy

Bio Pharma Dive

The regulator will issue a decision on lovo-cel by Dec. 20, roughly two weeks after a verdict is expected on a rival gene editing treatment from Vertex and CRISPR Therapeutics.

article thumbnail

Gene editing: beyond the hype

pharmaphorum

Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome. Zinc fingers.

article thumbnail

European regulators push Biogen, CRISPR drugs toward approval

Bio Pharma Dive

While a positive recommendation for the gene editing treatment Casgevy was expected, a clearance for Biogen’s Skyclaris, acquired through a recent acquisition, was no sure bet.

article thumbnail

Trailing rivals, Editas shares first study data for sickle cell treatment

Bio Pharma Dive

Editas said its gene editing therapy appeared safe and was well tolerated in two patients. regulators lifted a partial hold on the trial. The data comes five months after U.S.